In an Indian single-center phase III trial (D-TORCH) reported in the Journal of Clinical Oncology, Santhosh et al found that the nonsteroidal, anti-inflammatory topical diclofenac gel significantly reduced the risk of capecitabine-associated hand-foot syndrome vs placebo gel in patients with breast cancer or gastrointestinal cancer who were receiving capecitabine-based treatment.1
As stated by the investigators, “Hand-foot syndrome is a dose-limiting side effect of capecitabine. Celecoxib prevents hand-foot syndrome by inhibiting cyclooxygenase-2 (COX-2) that is upregulated because of the underlying associated inflammation. However, systemic side effects of celecoxib have limited routine prescription. Topical diclofenac inhibits COX-2 locally with minimal risk of systemic adverse events.”
In the double-blind trial, 264 patients at the All India Institute of Medical Sciences, New Delhi, were randomly assigned between February 2021 and January 2023 to receive topical diclofenac gel (n = 131) or placebo gel (n = 133). Patients applied gel on the palmar and dorsal surfaces of both hands twice daily for 12 weeks starting concurrently with capecitabine treatment and during four cycles of capecitabine treatment. The primary endpoint was the incidence of grade 2 or 3 hand-foot syndrome at 12 weeks.
Key Findings
At 12 weeks, grade 2 or 3 hand-foot syndrome was observed in 5 patients (3.8%) in the diclofenac group vs 20 (15%) in the placebo group (absolute difference = 11.2%, 95% confidence interval [CI] = 4.3%–18.1%, P = .003).
Grade 1 to 3 hand-foot syndrome was observed in 6.1% vs 18.1% of patients (absolute difference = 11.9%, 95% CI = 4.1%–19.6%). Grade 2 and grade 3 hand-foot syndrome was observed in 1.5% and 2.3% of patients in the diclofenac group vs 9.8% and 5.3% of the placebo group, respectively.
Capecitabine dose reductions due to hand-foot syndrome were required in 3.8% vs 13.5% of patients (absolute difference = 9.7%, 95% CI = 3.0%–16.4%). No discontinuations of capecitabine occurred due to adverse events. Grade 3 adverse events occurred in 11.5% vs 13.5% of patients, mainly diarrhea in both groups.
The investigators concluded, “Topical diclofenac prevented hand-foot syndrome in patients receiving capecitabine. This trial supports the use of topical diclofenac to prevent capecitabine-associated hand-foot syndrome.”
Disclosure: This research was supported by Alkem Laboratories Ltd and the Indian Association of Supportive Care in Cancer. For full disclosures of the study authors, visit ascopubs.org.
Reference
